Tumor-Antigen–Binding Bispecific Antibodies for Cancer Treatment  by Weidle, Ulrich H. et al.
Tumor-Antigen–Binding Bispeciﬁc Antibodies for
Cancer Treatment
Ulrich H. Weidle,a Roland E. Kontermann,b and Ulrich Brinkmanna
Bi- and multispecific antibody derivatives (bsAbs) can be considered as the next generation of
targeted biologics for c
recombinant antibody
bsAbs that bind at leas
specificities in compa
proteins, either as lar
multiple antigen-bindi
therapy currently incl
complete blockage o
blocking more than
pathways, also may lim
in the clinic as vehicle
Semin Oncol 41:653-6
This is an open acces
(http://creativecommo0093-7754/
& 2014 Th
This is an
(http://creat
http://dx.doi
Conflicts o
has an inte
aRoche Ph
Discover
Roche In
bInstitute o
Stuttgart
Address co
ceuticals
tion Cen
Germany
Seminarsancer therapy. The general concept of bsAbs is a physical connection of
-derived entities with at least two binding specificities. This generates
t two antigens or epitopes, thus altering their binding functionalities and
rison to “normal” antibodies. Most bsAbs are produced as recombinant
ge IgG-like proteins that contain Fc regions, or as smaller entities with
ng regions but without Fc. Application of bsAbs in experimental cancer
udes molecules that bind different cell surface proteins to achieve more
f proliferative or angiogenesis-associated pathways. This approach of
one pathway component, or to simultaneously hit complementing
it potential escape mechanisms of cancer cells. BsAbs also are applied
s to deliver immune effector cells and/or cytokines to tumors.
60 & 2014 The Authors. Published by Elsevier Inc. All rights reserved.
s article under the CC BY-NC-ND license
ns.org/licenses/by-nc-nd/3.0/).T
he concept of bispecific antibody derivatives
that target multiple antigens was demon-
strated more than 20 years ago by Sherie
Morrison and colleagues.1 Further development of
Bi- and multispecific antibody derivatives (bsAbs)
initially made rather slow progress mainly due to
technical hurdles. Today, however, progress in pro-
tein design and production technologies has led to
the availability of many different recombinant pro-
tein formats suitable for generation of bsAbs.2–16
Recombinant bsAb formats can be assigned to two
general classes: Fc-containing bsAbs (selected exam-
ples are shown in Figure 1A) and bsAb derivatives- see front matter
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Figure 1B). BsAbs that contain Fc are rather large
molecules (4100,000 kd) and frequently have a long
serum half-life. The long serum half-life of these
molecules is mediated by size (which minimizes
renal clearance) and predominantly by Fc-mediated
FcRn binding and antibody recycling. The “IgG-
derived molecules” are usually produced in mamma-
lian cells applying the same or similar production
technologies as those that are established for the
production of recombinant monospecific antibodies.
Compatibility of bsAb generation with established
upstream and downstream processes for production
of “normal” IgGs can facilitate drug development.
A variety of Fc-containing bsAb formats are cur-
rently available that have binding modules for addi-
tional antigen recognition attached to N- or C-termini
of IgG scaffolds. These include additional single-chain
or disulfide stabilized Fvs or Fabs fused to IgGs,
resulting in tetravalent molecules with bivalent bind-
ing specificity.3–5 In a similar manner, combinations
of single-chain variable fragments (scFvs) and scFabs
placed upon IgGs enable the production of multi-
valent (hexa- or even octavalent) molecules that can
recognize three (or more) different antigens.6
Dual-variable domain immunoglobulins are com-
posed in a similar manner, having extra VH and VL
domains of a second specificity placed upon the653
Figure 1. Design and composition of bsAbs. Bispeciﬁc antibodies can be large IgG-derived molecules containing Fc
regions (A), or smaller derivatives without Fc regions (B).
U.H. Weidle, R.E. Kontermann, and U. Brinkmann654N-termini of the V domains of IgGs.7,8 Bispecific “mini-
antibodies” are smaller than whole IgG-derived bsAbs
and are composed of single-chain variable fragments
(scFv) that are fused to the C-termini of the CH3
regions (CH3-scFv) and/or to the hinge region (scFv-
hinge-Fc) of an antibody. Another IgG-derived format is
the trivalent bsAb, which contains disulfide stabilized
variable domains fused to the C-terminus of CH3
domains of IgGs. These bsAb derivatives whose addi-
tional binding sites are stabilized by interchain disul-
fides can bind one antigen in a bivalent and another
antigen in a monovalent manner.9,10
Due to the bivalency of IgGs, bsAbs also can be
designed without fusing extra binding entities to the
IgG scaffold. Such molecules possess two binding
arms that recognize different antigens.
Display technologies can be applied to evolve
variable domains to recognize two unrelated antigens.11Recombinant antibodies with such variable domains
are “normal” IgGs, but still with bispecific function-
ality because they can bind two antigens with each
V-domain being occupied once. Other IgG-derived
bsAbs that enable monovalent (and simultaneous)
binding of different antigens are generated by forced
heavy (H)-chain heterodimerization, combined with
technologies that assure attachment of the correct
light (L)-chain to its respective H-chain. Antibody H-
chain heterodimer formation frequently can be
achieved via application of the “knobs-into holes“
technology that was pioneered quite early by
Genentech.12 BsAbs with knob-into-holes chains
contain replacements of small amino acids with
larger ones in one of their CH3 domains (“knob”)
and replacements of smaller amino acids (“hole”) in
the corresponding domain of the other H-chain. A
similar principle is applied for modulating H-chain
Tumor-antigen binding bispeciﬁc antibodies 655heterodimerization by strand-exchange engineering
(SEED)13 using sequence exchanges between IgG1
and IgA to create non-identical hetero-dimerizing
chains. L-chain mispairing must also be avoided to
generate homogenous preparations of bispecific
IgGs. The use of a “common light chain” principle
that combines two binders that share one light
chain but still have separate specificities14 is one
option for that. The recently developed CrossMab
technology,15,16 which avoids non-specific L-chain
mis-pairing by exchanging CH1 and CL domains in
the Fab of alf of the bispecific antibody is another
robust technology to generate homogeneous bsAbs.
BsAbs that are composed of such cross-over
domains fully retain the binding specificity and
affinity (and correct VL–VH chain pairing) of their
parent antibodies.BsAbs WITHOUT Fc REGIONS
BsAbs that do not carry Fc regions are frequently
of a smaller size than Fc-containing antibody deriv-
atives. They are frequently produced in yeast or
bacterial expression systems, and hence cannot be
purified by technologies that are “standard” for the
production of IgGs. Most of bsAbs without Fc have a
short serum half-life due to their small size (renal
clearance) and due to the lack of interaction with the
neo-natal Fc receptor.17 On the other hand, tissue
penetration of such small proteins molecules may be
better compared to large IgG-like entities. The
pharmacokinetics of small bsAbs can be modulated
and serum half-life prolonged by conjugation with
polymers such as polyethylene glycol,18 or by fusion
to albumin binding entities.17,19
Bispecificity is achieved by connecting individual
binding modules such as scFvs or Fabs of different
specificities to each other via flexible linker pep-
tides. The connection of the different binding part-
ners is either achieved by recombinant protein
fusion, or by attachment of heterodimerization
(and/or trimerization) functionalities.
One clinically applied example for bsAbs without
Fc regions are BiTEs, bispecific T-cell engagers,20
which are generated by fusing two scFvs to each
other by a flexible linker peptide. Diabodies are
another well-established and robust technology to
generate bispecific binders lacking constant region
sequences.21,22 They contain two VH and two VL
domains from two different antibodies, connected
with short linker peptides in a manner that permits
only the association of the correct VH-VL hetero-
dimers. In diabodies, the VH of the first binder is
linked to the VL of the second binder, which is co-
expressed with the VH of the second antibody
linked to VL of the first antibody. A modification
of the diabody technology generates tetravalenttandem antibodies (TandAbs).21 These molecules
assemble by dimerization of a protein that contains
four antibody variable H- and L-chains in an orienta-
tion that again prevents “wrong” intramolecular
pairing. Another similar modification results in dual
affinity retargeting molecules (DARTs), antibody
derivatives that are stabilized by disulfide bonds
but otherwise apply a similar design concept as
diabodies.23 Many other concepts that are applied
to generate small bsAb derivatives were recently
summarized.2 One example is the “dock-and-lock”
principle, which is based on heterodimerization of
cyclic adenosine monophosphate (cAMP)-dependent
protein kinase A and A-kinase anchoring protein24
and is used to design dimerization and docking
domains. These domains are linked to Fab fragments
to assemble first a divalent Fab fragment, and in turn
creating another docking site for binding to an
attachment sequence incorporated into a second
protein, resulting in the formation of a trivalent
complex.BsAbs IN CANCER THERAPY—RECRUITMENT
OF IMMUNE EFFECTOR CELLS
Technical hurdles had hampered the develop-
ment of bsAbs in the past. Although many promis-
ing molecules of different formats are currently in
explorative or preclinical stages, still rather few are
in clinical development. BsAbs that are currently in
the clinic or in clinical development are listed in
Table 1. These include molecules that bind differ-
ent tumor-associated antigens (dual targeting) to
achieve more complete blockage of proliferative or
angiogenesis-associated pathways, or molecules for
targeted delivery of immune effector cells and/or
cytokines to tumors.
“First-generation” multispecific antibody prepara-
tions that have been applied in the clinic are trifunc-
tional bsAbs developed by Trion Pharma (Munich,
Germany). The technology for producing these (non-
human) bsAbs has been quite unusual because Rat/
mouse quadromas were used as expression vehicles.
These quadromas generate IgG-like bsAbs with a
correct H/L-chain pairing because species-specific
chains preferentially assemble with each other.25
The bsAbs are a hybrid of mouse IgG2a and rat
IgG2b. They have three functionalities as they target
a tumor antigen, they recruit T-effector cells via CD3
binding, and they can activate natural killer cells,
monocytes/macrophages, and dendritic cells via
binding of Fc to Fcγ-receptors.26 A series of bsAbs
were generated with this technology, including
bsAbs that target epithelial cell adhesion molecule
(EpCAM), HER2, CD20, or gangliosides GD2 and
GD3.27–33 All of these showed activity in preclinical
Table. 1. Bispeciﬁc Antibodies in Clinical Development
Target
Combination bsAb Format Status Reference
EpCAMx CD3
(xFcγR)
Catumaxomab Large with Fc
quadroma-
bsAb
Approved 2007 malignant ascites,
phase II ovarian, gastrointestinal,
non-small cell lung cancer, breast
cancer; phase I/II peritoneal
carcinomatosis
64
CD20 x CD3
(xFcγR)
Bi 20, FBTA-05 Large with Fc
quadroma-
bsAb
Phase I non-Hodgkin lymphoma 64
CD30xCD16, AFM-13 Without Fc Phase I 65
TandAb Hodgkin lymphoma
CD3xCD19 Blinatumomab Small without Fc Phase II non-Hodgkin lymphoma
(DLBCL), acute lymphocytic
leukemia
66
AMG-103, MT-
103
BiTE
CD3xEpCAM Solitomab, MT-
110, AMG-110
Small without Fc Phase I solid tumors 67
BiTE
CD3xCEA MT-111, MEDI-
565
Small without Fc Phase I advanced gastrointestinal 68
BiTE
CD3xPSMA, BAY-2010112,
MT-112.
Small without Fc Phase I, prostate cancer 69
BiTE
HER2xHER3, MM-111, Without Fc scFv-
(mHSA)-scFv
Phase I breast, stomach, and
esophageal cancer
55
HER3xIGF-1R MM-141 Large with Fc Phase I colid tumors 70
IgGþscFv
EGFRxHER3, RG-7597 Large with Fc
two-in-one IgG
Phase II metastatic colorectal cancer,
head and neck stem cell cancer
60
MEHD-7945A
Ang2xVEGF-A RG-7221 Large with Fc Phase I advanced solid tumors,
avastin-resistant tumors
63
CrossMab
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EpCAM/anti-CD3 bsAb, was brought into the clinic27
and efficiently eliminated tumor cells in patients
with ovarian carcinoma and prevented accumulation
of ascites. The molecule has an acceptable safety
profile, with very small doses (5–20 mg) being
administered four to five times by intraperitoneal
infusions within 9–13 days. Due to the non-
humanness of the bsAb, moderate anti-mouse or
anti-rat responses were observed in most patients;
however, this did not affect the efficacy of the
treatment. Another bsAb produced by the same
technology is ertumaxomab (anti-HER2/anti-CD3),
which has progressed into clinical studies in patients
with metastatic mammary carcinoma.33
Another technical approach to bsAbs for recruit-
ment of immune effector cells is the development of
bipecific T-cell Engagers (BiTEs).34,35 In contrast to
the quadroma-derived IgG-derivatives which contain
Fc regions, BiTEs are small and have a short serum
half-life. They consist of two scFvs connected by a
flexible linker35–37 with one Fv directed at a tumor
cell surface antigen, and the second scFv binding the
CD3έ subunit of the T-cell receptor complex. BiTEsare produced as recombinant proteins in Escherichia
coli. Potent anti-tumor cell cytotoxicity has been
observed for many BiTEs,38 inducing specific target
cell lysis in cell culture assays at concentrations
ranging between 10 pg/mL and 10 ng/mL.39 BiTEs
elicit repeated rounds of target cell lysis by T cells at
very low effector/ target (E/T) cell ratios,40 with
T-cells killing being mediated by membrane perfo-
ration and subsequent induction of granzymes and
apoptosis.41 It is important to note that the affinity of
the antibody directed against the tumor-associated
antigen is much higher than that directed against
CD3.35 A series of BiTEs that bind different tumor
cell surface antigens have been generated, including
molecules that target CD19, EpCAM, HER2, carci-
noembryonic antigen (CEA), ephrin A2 (EphA2),
CD33, and melanoma-associated chondroitin sulfate
proteoglycan (MCSP). Blinatumomab36 is an anti-
CD19/anti-CD3 BiTE with excellent potency leading
to tumor eradication in many preclinical mod-
els.42,43. In patients, blinatumomab successfully
depletes chronic lymphocytic leukemia (CLL) B cells
in the presence of autologous T cells. This included
patients that had been pretreated with different
Tumor-antigen binding bispeciﬁc antibodies 657chemotherapy regimens.44 Tumor regression also
was observed in non-Hodgkin lymphoma patients.45
Blinatumomab is applied at low doses (as low as
0.005–0.06 mg/m2), the relatively short half-life of
BiTEs also requires an appropriate dosing schedule
and formulation to ensure continuous activation of T
cells against target cells. Other BiTEs that are in
clinical studies are composed of EpCAM, prostate-
specific membrane antigen (PSMA), or CEA-binding
molecules combined with CD3-binding modules
(Table 1).
TandAbs are tetravalent, bispecific fusion proteins
that were developed for the recruitment of immune
effector cells.46 In contrast to BiTEs, TandAbs have
four binding sites, and they are larger than BiTEs but
do not carry Fc domains. Nevertheless, they have a
longer serum half-life than BiTEs because they are
larger than the cut-off size for glomerular filtration.
AFM13 is a CD30- and CD16A-binding Tandab that
has shown good preclinical activity by recruitment
of natural killer cells and macrophages.47 AFM13
(CD30xCD16A) entered clinical studies for the treat-
ment of Hodgkin lymphoma.BsAbs DIRECTED AT RECEPTOR-TYROSINE
KINASES
The Her family of receptor-tyrosine kinases
(RTKs) has four members, HER1/EGFR, HER2,
HER3, and HER4. Various heterodimer constellations
of these receptors (HER1, 2, 3) are receptors for
epidermal growth factor (EGF)-related ligands.
Ligand binding, in turn, can induce RTK activity,
trigger intracellular signaling cascades, and promote
tumor growth.48 For example, HER2 is overex-
pressed in up to 30% of breast carcinomas, which
correlates with a shorter time to relapse and shorter
overall survival.49 HER3 also is involved in breast
cancer development and progression, as phosphor-
ylation of HER3 was observed in HER2-amplified
breast cancer.50 HER2–HER3 heterodimerization
leads to breast cancer cell proliferation and is
involved in transformation.51 Monospecific antibod-
ies that bind to and interfere with signaling of Her
family members, such as cetuximab (erbitux, HER1)
or trastuzumab (herceptin, HER2) are successfully
applied in cancer therapy. Due to extensive cross-
talk between HER family members and signaling
events, BsAbs directed at multiple members of the
Her family are developed with the rationale that
addressing more than one member of this family
might improve therapeutic efficacy.52,53 For exam-
ple, HER2-binding trastuzumab and pertuzumab by
themselves are rather poor inhibitors of ligand-
induced HER3 activation,54,55 but bsAb-mediated
targeting of both HER2 and HER3 can stop thegrowth of cancer cell lines with amplified HER2.56
One bsAb in phase I study that binds HER2 as well as
HER3 is MM-111. It is composed of two antagonistic
scFvs that bind HER2 and HER3, which are linked to
each other as well as to a modified human serum
albumin to modulate the pharmacokinetics of the Fc-
less molecule.55 MM-111 binds to and forms com-
plexes with HER2 and HER3, and potently inhibits
the proliferation of tumor cells in vitro and in vivo,
with efficacy depending on HER2 expression.
Another bsAb in phase I study is MM141, which
bind HER3 as well as insulin-like growth factor (IGF)-
1R, another RTK that is not a member of the HER
family. MM141 is composed of scFvs that are added
to the Fc regions of an IgG. The rationale for
combining IGF-1R and HER3 binding specificities
into one bsAb is the observation that IGF-1R signal-
ing also is deregulated in many types of cancer.57–60
Thus, simultaneous inhibition of HER3- and IGF-1R
signaling could be a valid therapeutic strategy to
overcome escape of tumor cells.
A bsAb that binds to EGFR (HER1), as well as to
HER3 that is in a phase II trial is RG7597
(MEDH7945A). This molecule is an IgG whose bind-
ing regions have been evolved to permit effective
binding to EGFR, as well as to HER3 with good
affinities (1.9 and 0.4 nmol/L, respectively).61 As a
human IgG1, MEHD7945A interferes not only with
EGFR and HER3 signaling, but—due to the presence
of Fc—also can exert immune effector functions.
The rationale for combining HER1- and HER3 bind-
ing specificities into one bsAb is the observation that
complete inhibition of MAPK and AKT signaling (and
subsequent growth arrest of pathway addicted cells)
can be achieved when EGFR and HER3 are blocked
simultaneously. Thus, simultaneous inhibition of
HER1 and HER3 could be a valid therapeutic strategy
to improve tumor therapy.60BsAbs IN CANCER THERAPY—INTERFERENCE
WITH TUMOR ANGIOGENESIS
Antibody-mediated interference with tumor vas-
cularization can be applied for the treatment of solid
tumors. Tumor angiogenesis is controlled and modu-
lated by multiple angiogenic factors. In conse-
quence, tumors may become resistant towards anti-
angiogenic treatments that inactivate only one factor
(eg, vascular endothelial growth factor [VEGF]) by
activation of alternative pathways.61,62,63 Simultane-
ous depletion of multiple factors or interference
with multiple angiogenesis pathways may therefore
improve anti-angiogenic therapy by reducing poten-
tial escape mechanisms, eg, due to activation of
alternative pathways.62,63 One anti-angiogenic bsAb
currently in phase I clinical trials binds to and
U.H. Weidle, R.E. Kontermann, and U. Brinkmann658inhibits the functionality of VEGF-A, as well as
angiopoietin-2 (Ang2). VEGF is the target of mono-
specific antibody bevacizumab (avastin) and binds to
VEGF receptor 1 (VEGFR1) and VEGFR2, which in
turn promotes and modulates angiogenesis. Ang2 is a
ligand of the Tie-2 kinase, which also contributes to
and modulates tumor angiogenesis. The bsAb that
binds VEGF-A and Ang-2 is an IgG-like “CrossMab”
with a shape and size and pharmacokinetic param-
eters of normal IgGs.15,16,61 Preclinical evaluation
revealed better activity of the bsAb in comparison to
the monospecific VEGF-A–binding (bevacizumab) or
Ang-2–binding antibody. The bispecific CrossMab
administered at the equivalent dose in terms of
binding sites mediated the best tumor growth inhib-
ition compared to monospecific parent antibodies or
combinations thereof.61REFERENCES
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